Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders (2014 - 2026)
Rocket Pharmaceuticals (RCKT) reported Net Income towards Common Stockholders of -$47.6 million for Q1 2026, up 22.4% on a YoY basis from -$38.9 million in Q1 2025, and down 11.89% sequentially from -$42.5 million in Q4 2025.
Rocket Pharmaceuticals (RCKT) Net Income towards Common Stockholders (2014 - 2026) Analysis & Trends
Rocket Pharmaceuticals (RCKT) has 13 years of Net Income towards Common Stockholders data on file, last reported at -$47.6 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 22.4% year-over-year to -$47.6 million; the trailing twelve-month figure through Mar 2026 stood at -$209.4 million (up 18.85% YoY), and the FY2025 full-year result was -$223.1 million, up 13.77% from the prior year.
- Net Income towards Common Stockholders retreated to -$47.6 million in Q1 2026, from -$42.5 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$42.5 million in Q4 2025 to a low of -$69.6 million in Q2 2024.
- A 5-year average of -$58.6 million and a median of -$60.3 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders tumbled 57.57% in 2022 and advanced 29.49% in 2025, its largest moves.
- Tracing RCKT's Net Income towards Common Stockholders over 5 years: stood at -$66.7 million in 2022, then gained by 10.59% to -$59.7 million in 2023, then decreased by 1.12% to -$60.3 million in 2024, then increased by 29.49% to -$42.5 million in 2025, then slipped by 11.89% to -$47.6 million in 2026.
- Business Quant data shows RCKT's Net Income towards Common Stockholders at -$47.6 million in Q1 2026, -$42.5 million in Q4 2025, and -$50.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Rocket Pharmaceuticals | 359.39 Mn | 359.39 Mn | - | -47.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.59 Mn |
| Dec 31, 2025 | -42.54 Mn |
| Sep 30, 2025 | -50.33 Mn |
| Jun 30, 2025 | -68.92 Mn |
| Mar 31, 2025 | -61.33 Mn |
| Dec 31, 2024 | -60.33 Mn |
| Sep 30, 2024 | -66.72 Mn |
| Jun 30, 2024 | -69.65 Mn |
| Mar 31, 2024 | -62.05 Mn |
| Dec 31, 2023 | -59.66 Mn |
| Sep 30, 2023 | -61.90 Mn |
| Jun 30, 2023 | -65.70 Mn |
| Mar 31, 2023 | -58.34 Mn |
| Dec 31, 2022 | -66.72 Mn |
| Sep 30, 2022 | -57.76 Mn |
| Jun 30, 2022 | -54.40 Mn |
| Mar 31, 2022 | -42.98 Mn |
| Dec 31, 2021 | -44.25 Mn |
| Sep 30, 2021 | -50.12 Mn |
| Jun 30, 2021 | -34.53 Mn |